Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Radiopharm Theranostics Limited (AU:RAD)
ASX:RAD
RESEARCH TOOLSreports
Holding AU:RAD?
Track your performance easily
RAD Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.02 - AU$0.10
Previous CloseAU$0.03
Volume337.52K
Average Volume (3M)5.95M
Market Cap
AU$54.32M
Enterprise ValueAU$27.34M
Total Cash (Recent Filing)AU$26.98M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Feb 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares OutstandingN/A
10 Day Avg. Volume2,307,386
30 Day Avg. Volume5,951,921
Standard Deviation0.20
R-Squared0.04
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)2760.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.24Price Target Upside860.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Radiopharm Theranostics Limited News
PremiumCompany Announcements
Radiopharm Theranostics Marks Progress and Expands US Access
PremiumCompany Announcements
Radiopharm Theranostics Announces 2024 AGM for Shareholders
PremiumCompany Announcements
Radiopharm Theranostics Director Increases Shareholding
PremiumCompany Announcements
Radiopharm Theranostics Partners with BAMF Health for Brain Cancer Study
PremiumCompany Announcements
Radiopharm Appoints New Director, No Securities HeldPremiumCompany Announcements
Radiopharm Advances Cancer Radiotherapy Drug
PremiumCompany Announcements
Radiopharm Theranostics Appoints New Financial Expert
PremiumCompany Announcements
Radiopharm Advances Commitment to ESG PrinciplesBulls Say, Bears Say
Bulls Say
Clinical TrialsThe FDA approved the Investigational New Drug application for a Phase IIb imaging trial of RAD 101 in brain metastases, marking a significant regulatory milestone.
Market ExpansionRadiopharm announced the launch of American Depository Shares, which will be traded in the U.S. over-the-counter market as RADTY, with plans for a secondary listing on Nasdaq.
Therapeutic PipelineRadiopharm Theranostics has focused its therapeutic pipeline on biologically validated targets that have seen limited or no use in radiopharmaceuticals, which is designed to de-risk development and limit competition.
Bears Say
Capital DilutionThe AUD 70M capital raised resulted in substantially higher dilution.
Financial StrategyThe capital that Radiopharm raised was necessary to fund operations, but the associated prices were lower than previous estimates, resulting in substantially higher dilution.
Stock ValuationThe AUD 70M raised by Radiopharm had prices lower than previous estimates, leading to significantly higher dilution.
---
Options Prices
Currently, No data available
---
Ownership Overview
RAD FAQ
What was Radiopharm Theranostics Limited’s price range in the past 12 months?
Radiopharm Theranostics Limited lowest share price was AU$0.02 and its highest was AU$0.10 in the past 12 months.
What is Radiopharm Theranostics Limited’s market cap?
Currently, no data Available
When is Radiopharm Theranostics Limited’s upcoming earnings report date?
Radiopharm Theranostics Limited’s upcoming earnings report date is Feb 26, 2025 which is in 95 days.
How were Radiopharm Theranostics Limited’s earnings last quarter?
Radiopharm Theranostics Limited released its earnings results on Aug 29, 2024. The company reported -AU$0.052 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.042.
Is Radiopharm Theranostics Limited overvalued?
According to Wall Street analysts Radiopharm Theranostics Limited’s price is currently Undervalued.
Does Radiopharm Theranostics Limited pay dividends?
Radiopharm Theranostics Limited does not currently pay dividends.
What is Radiopharm Theranostics Limited’s EPS estimate?
Radiopharm Theranostics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Radiopharm Theranostics Limited have?
Radiopharm Theranostics Limited has 2,172,960,700 shares outstanding.
What happened to Radiopharm Theranostics Limited’s price movement after its last earnings report?
Radiopharm Theranostics Limited reported an EPS of -AU$0.052 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went up 33.333%.
Which hedge fund is a major shareholder of Radiopharm Theranostics Limited?
Currently, no hedge funds are holding shares in AU:RAD
---
Radiopharm Theranostics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.24 (860.00% Upside)
AU$0.24 (860.00% Upside)
Blogger Sentiment
Bullish
AU:RAD Sentiment 66%
Sector Average 73%
Sector Average 73%
Insider Transactions
Bought Shares
Worth AU$3.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.35%
12-Months-Change
Fundamentals
Return on Equity
-132.26%
Trailing 12-Months
Asset Growth
-3.89%
Trailing 12-Months
Company Description
Radiopharm Theranostics Limited
Radiopharm Theranostics Ltd is a clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development.
---
RAD Stock 12 Month Forecast
Average Price Target
AU$0.24
▲(860.00% Upside)
Technical Analysis
Best Analysts Covering RAD
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-27.68%
reiterated a buy rating 24 days ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -27.68% per trade.
---